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Objectives: Several histological scoring systems, including the focus score, performed in minor salivary
glands (MSGs) by hematoxylin–eosin (H&E) staining, have been employed in clinical practice to assess
the inﬂammatory inﬁltrate and provide the diagnosis of primary Sjögren's syndrome (pSS). Aims of this
study were to integrate different scoring systems and identify potential differences in the molecular
proﬁle of lymphoid cytokines related to germinal center (GC) formation and clinical subsets in pSS.
Methods: Overall, 104 pSS patients and 40 subjects with sicca non-pSS were retrospectively evaluated.
MSG biopsies were evaluated by H&E and immunoﬂuorescence to assess histological pattern, Chisholm
and Mason grading system, Tarpley score, a grading for the severity of inﬂammatory inﬁltrate, T-/B-cell
segregation, and the presence of GC. MSGs from 50 pSS patients and 30 sicca non-pSS patients were
processed by real-time PCR to assess LTα, LTβ, BAFF, CXCR4, CXCL12, CXCR5, CXCL13, CCR7, CCL19,
and CCL21.
Results: GCs presence was associated with anti-Ro/SSA and anti-La/SSB antibodies, hypergammaglobu-
linemia, salivary gland swelling, higher Tarpley score and focus score, and extraglandular involvement
but, at multivariate analysis, only extraglandular involvement was independently associated to GC. pSS
patients displayed higher level of all cytokines compared to those with sicca symptoms. GCþ pSS
patients displayed higher level of all cytokines compared to those GC .
Conclusions: Our study demonstrates that different histopathological patterns, including GC presence,
reﬂect different cytokine expression and different clinical subsets. We believe that the combined
immunoﬂuorescence/molecular approach in MSGs would help to tailor diagnostic and therapeutic
approach for different subsets of pSS patients.
& 2014 Elsevier Inc. All rights reserved.Introduction
Primary Sjögren's syndrome (pSS) is a systemic autoimmune
disease characterized by mucosal dryness and, in at least one-third
of patients, by extraglandular involvement, with musculoskeletal,ld be attributed: Department
Unit, University of L'Aquila,
bbi).
.cutaneous, renal, pulmonary, or neurological manifestations [1].
Furthermore, 5% of patients may develop lymphoma, mainly the
mucosa-associated lymphoid tissue (MALT) non-Hodgkin lym-
phoma (NHL), which represents the most severe complication of
the disease [2,3]. At present, although several pathogenic mecha-
nisms have been suggested trying to understand the clinical
heterogeneity of the disease, several aspects remain unknown. In
this setting, putative biomarkers able to identify different clinical
subsets and eventually disease outcome are still lacking.
Minor salivary glands (MSGs) of patients with pSS show a focal
lymphocytic sialadenitis (FLS) characterized by the presence of one
or more dense aggregates with 50 or more lymphocytes, usually
F. Carubbi et al. / Seminars in Arthritis and Rheumatism ] (2014) ]]]–]]]2located in the perivascular or periductal areas, in 4 mm2 of
glandular tissue [4]. In addition to FLS, different morphologic
patterns of chronic inﬂammation commonly occur in MSG biopsy
specimens: non-speciﬁc chronic sialadenitis (NSCS) and sclerosing
chronic sialadenitis (SCS) [5]. Different histological scores have
been employed to describe glandular involvement during pSS
[6–10], and as far as MSGs histology is concerned, its diagnostic
role is widely accepted and currently considered the “gold stand-
ard.” Indeed, MSG biopsy is considered 1 of the 4 objective criteria
of American–European Consensus Group's classiﬁcation and 1 of
the 3 objective criteria of American College of Rheumatology's
classiﬁcation for pSS [11,12].
However, although the practical role of the biopsy is commonly
accepted, a recent meta-analysis pointed out that a very low
number of studies are available to support its diagnostic usefulness
[13], suggesting that further studies aimed to conﬁrm the diag-
nostic role of MSG biopsy and possibly to correlate MSGs histo-
pathology with clinical picture are needed.
The spectrum of MSG histopathological damage ranges from
mild to diffuse inﬁltrates with progressive loss of normal glandular
tissue. T-cells predominate in mild lesions, whereas B-cells are the
most represented cell subset in the advanced lesions, with a
decrease in the percentage of macrophages and an increased
percentage of DCs [14–16].
Inﬁltrating lymphocytes are often organized into tertiary ectopic
lymphoid structures, showing a network including speciﬁc segre-
gated T- and B-cell zones associated to follicular dendritic cells (fDCs).
Some of these ectopic lymphoid structures mirror classical germinal
centers (GCs) [17,18]. This organization in lymphoid GC-like struc-
tures is well documented in pSS and can be detected in one-third of
patients [19]. GC-like structures contain the machinery required for
antibody production, and it has been reported that pSS-speciﬁc
autoantibodies may be directly generated by plasma cells located in
MSG-organized inﬁltrates [19,20]. GC-like structures in MSGs are
associated with (i) higher frequency of extraglandular manifestations,
(ii) higher focus score, (iii) hypergammaglobulinemia, (iv) higher
levels of circulating rheumatoid factor, and (v) higher prevalence of
circulating anti-Ro (SSA)/anti-La (SSB) autoantibodies in sera. Fur-
thermore, it has been suggested that GC-like structures may correlate
with later lymphoma development [21–23]. Moreover, patients
developing GC-like inﬁltrates display a different genetic, serological,
and glandular cytokine proﬁle when compared to those without GCs
[24–27].
The pathogenesis of pSS is a complex mechanism strongly
mediated by different effectors cells and their products. It is now
well established that T-cells largely inﬁltrate affected salivary
glands leading to an upregulation of Th1- and Th17-associated
cytokines. Besides these proinﬂammatory mediators, including
interferon α and γ, tumor necrosis factor α, and interleukin
(IL)-12 and IL-18, other cytokines involved in T- and B-cell
activation and autoantibody production, such as IL-6, are overex-
pressed. In contrast, pivotal anti-inﬂammatory mediators, includ-
ing IL-4 and transforming growth factor β, are expressed at low
levels [28]. In this contest, Th17 cells represent the major source of
several proinﬂammatory cytokines, such as IL-17, IL-21 and IL-22
[29], and the IL-23/IL-17 pathway is known to play a central role in
autoimmunity and chronic inﬂammation in pSS [30].
Although the presence, and sometimes predominance, of T cells in
salivary gland inﬁltrates underscores their potential contribution to
the pathogenesis of pSS [29,31–33], growing evidence suggest a
central role of B cells in the development of the disease [34]. Indeed,
B lymphocyte hyperactivity and prolonged B-cell survival as well as
their aberrant activity may lead to the development of NHL [2,35].
B-cell activating factor (BAFF) is involved in B-cell survival and
humoral immune responses and plays a critical role in B-cell
homeostasis [36]. BAFF overexpression, observed in serum, saliva,and MSGs of pSS patients, particularly those with GCs, rescues
auto-reactive cells from depletion in the periphery, leading to
higher number of mature auto-reactive B cells [24,37–41].
Evidence from animal models and patients with pSS demon-
strated that the formation and maintenance of tertiary lymphoid
tissues are critically dependent on ectopic expression of lympho-
toxins and homeostatic chemokines such as CXCL13, CXCL12,
CCL19, and CCL21 and interaction with their speciﬁc receptors,
CXCR5, CXCR4, and CCR7, respectively. These key molecules are
produced during chronic inﬂammation by several cell types,
including resident epithelial, stromal, and endothelial cells, as well
as different subsets of inﬁltrating immune cells [17,42].
The lymphotoxin-alpha (LTα) and lymphotoxin-beta (LTβ) path-
ways have also been associated with the presence of ectopic
lymphoid structures at the sites of chronic inﬂammation in several
autoimmune diseases [43]. Furthermore, when compared with the
inﬂammatory process of non-speciﬁc sialadenitis, salivary glands
of patients with pSS have been found to express a unique proﬁle of
cytokines, including a striking overexpression of CXCL13 and, to a
lesser degree, CXCL12 [44–48]. Furthermore, CXCL12–CXCR4 and
CXCL13–CXCR5 interactions have been suggested to be involved in
B-cell deregulation, preferential migration of CXCR4- and CXCR5-
expressing CD27þ memory B-cells into the inﬂamed salivary
glands, the development of ectopic GC-like structures as well as
the peripheral B-cell abnormalities [49,50].
CCL21 is progressively increased with the gradual acquisition of
lymphoid features in pSS salivary glands [44], while animal models
of MSG inﬂammation show the role of CCR7/CCL19–CCL21 axis in
the inducible ectopic lymphoid tissue formation [51]. The presence
of CCL19/CCL21 allows the homing of T-cells, mature DCs, and to a
lesser extent, of CCR7-expressing naïve B-cells to secondary
lymphoid organs from the systemic circulation [52–54].
Although histological studies, and in consequence pSS diagno-
sis, are mainly based on hematoxylin–eosin (H&E) staining, new
approaches, such as immunoﬂuorescence or molecular biology
assays, allow to stratify pSS patients according to other variables
including GC presence and cytokine expression. Such evaluations
might represent a powerful tool to predict pSS clinical picture and
possibly the disease prognosis in clinical practice.
Taken the well-known role of the aforementioned molecules in
the organization of MSG lymphoid inﬁltrates and the lack of a
correlation between histological patterns and clinical picture, we
investigated the relationship between the characteristic of the
immune inﬁltrate, including the presence of GC-like structures, the
molecular expression of different cytokines, and laboratory and
clinical features in a large cohort of pSS patients.Methods
Study population
Overall, 104 pSS patients (98 females and 6 males) referring to
the Rheumatology Unit, University of L'Aquila, Italy, or to the
Rheumatology Unit, University of Perugia, Italy, from September 1,
2009 to December 31, 2013 were retrospectively evaluated. All
patients were over 18 years old, fulﬁlled the American–European
consensus criteria for pSS, including histopathologic criteria [11],
and we excluded patients with SS associated to one or more
systemic-/organ-speciﬁc autoimmune diseases. A total of 40 sub-
jects with sicca symptoms, of whom (i) 20 (16 women and 4 men)
with normal MSGs and absence of any clinical and serological
feature of pSS and (ii) 20 (15 women and 5 men) without any
clinical and serological feature of pSS, but showing different grade
of MSG inﬂammation (NSCS) without FLS, acted as controls. Both
pSS patients and subjects with sicca symptoms did not display
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recorded at the time of diagnosis. The whole study was approved
by the local Ethic Committees. Written informed consent was
obtained from all subjects, in accordance with the declaration of
Helsinki.
Histological analysis of MSG biopsies
Labial MSG biopsies were obtained from all patients and
controls at the time of biopsy collection for differential diagnosis
of sicca symptoms, according to international guidelines. All
sections were randomly analyzed by 2 expert observers, blinded
to clinical and molecular data. Each sample was independently
evaluated, and any discrepancies were resolved by consensus.
For histological evaluation, H&E-stained sections were assessed
as follows: (i) the histological pattern (normal, NSCS, or FLS) [5];
(ii) the Chisholm and Mason grading system (grades 0–4) [6];
(iii) the Tarpley score (scores 0–4) [7]; (iv) a grading for the
severity of inﬂammatory inﬁltrate (grades 1–5) [9,10]; and (v) the
focus score, assessing the number of foci/4 mm2 (a focus is deﬁned
as an aggregate including at least 50 mononuclear cells) [8]. A
biopsy was considered GC positive (GCþ) if displaying at least one
focus with lymphoid-like organization within normal MSG tissue.
Focal inﬁltrates without lymphoid organization were classiﬁed as
GC negative (GC) [27].
Both cellular inﬁltrate and lymphoid organization were
assessed by immunoﬂuorescence staining of sequential sections
with monoclonal antibodies recognizing CD3, CD20, and CD21 (all
provided by DakoCytomation, Glostrup, Denmark). Formalin-ﬁxed
and parafﬁn-embedded sections, measuring 3 μm in thickness,
were dewaxed and rehydrated. All sections underwent high-
temperature antigen retrieval using Target Retrieval Solution
(Dako, Glostrup, Denmark) for 35 min at 951C, except for sections
stained with anti-CD21, which underwent proteolytic digestion for
7 min at 371C using proteinase K (Dako, Glostrup, Denmark).
For sections stained with anti-CD3 or anti-CD21, we performed
nonspeciﬁc binding blocking (Protein Block Serum-Free ready-to-
use; Dako, Glostrup, Denmark). For sections stained with anti-
CD20, we also performed endogenous biotin blocking (Avidin–
Biotin blocking system; Vector Laboratories, Burlingame, CA).
To assess T-/B-cell segregation, sections were double stained
with anti-CD3/anti-CD20 antibodies. Monoclonal mouse anti-
human CD3 (dilution 1:50) was incubated for 1 h at room temper-
ature in wet chamber, followed by an incubation of 30 min with
secondary antibody goat anti-mouse/Alexa Fluor-555 (1:100)
(Invitrogen, Paisley, UK). Subsequently, monoclonal mouse anti-
human CD20 (1:20) incubation was performed for 1 h at room
temperature in wet chamber, followed by 30 min incubation with
biotin goat anti-mouse IgG (1:100) (Biolegend, San Diego, CA) and
30 min incubation with streptavidin/Alexa Fluor 488 (1:200)
(Invitrogen, Paisley, UK).
To detect fDC networks and identify GCs, sections were incubated
overnight at 41C with monoclonal mouse anti-human CD21 (1:20)
followed by an incubation of 30 min with secondary antibody goat
anti-mouse/Alexa Fluor 488 (1:100) (Invitrogen, Paisley, UK).
All sections were counterstained with 40,6-diamidino-2-
phenylindole (DAPI; 1:1000) for 10 min, and slides were mounted
with Mowiol 4-88 (Sigma-Aldrich, Milan, Italy). Images were
acquired using an Olympus BX53 ﬂuorescence microscope with
cellSens software (Olympus America Inc., Center Valley, PA).
RNA isolation and quantitative real-time polymerase chain reaction
(qRT-PCR)
Of 104 MSG specimens obtained from pSS patients, 50 were
stored for molecular analysis. To avoid any biases due to B-cellmonoclonal expansion, we excluded from molecular analysis the
specimens obtained from the 2 pSS patients in which the diagnosis
of B-cell lymphoma was reported. A total of 10 normal MSGs and
20 MSGs with NSCS acted as control groups. Total RNA was
extracted from MSGs using TRIZOL (SIGMA, St. Louis, MO) and
reverse transcribed into complementary DNA (cDNA) with the
ThermoScript reverse transcription-polymerase chain reaction
system (Invitrogen, Carlsbad, CA). The qRT-PCR was performed
by using SYBR green kits and Taqman gene expression assays
(Applied Biosystems, Utrecht, the Netherlands). Results were
analyzed after 40 cycles of ampliﬁcation using the ABI 7500 Fast
Real Time PCR System (Applied Biosystems, Utrecht, the Nether-
lands). Primers were designed on the basis of the reported
sequences (PrimerBank NCBI): LTα—50-ATGACACCACCTGAACG-
TCTC-30 (forward) and 50-CTCTCCAGAGCAGTGAGTTCT-30 (reverse);
LTβ—50-GACGAAGGAACAGGCGTTTCT-30 (forward) and 50-GTAGCC-
GACGAGACAGTAGAG-30 (reverse); β-actin—50-CCTGGCACCCAGCA-
CAAT-30 (forward) and 50-AGTACTCCGTGTGGATCGGC-30 (reverse);
CXCR5—50-CACGTTGCACCTTCTCCCAA-30 (forward) and 50-CGCCA-
CATGGTAGAGGAATCG-30 (reverse); CXCL13—50-GCTTGAGGTGTA-
GATGTGTCC-30 (forward) and 50-CGATCAATGAAGCGTCTAGGGAT-30
(reverse); CXCR4—50-GACTTGTGGGTGGTTGTG-30 (forward) and
50-AGGATGAGGATGACTGTGG-30 (reverse); CXCL12—50-GAGCCAA-
CGTCAAGCATCTC-30 (forward) and 50-CAATGCACACTTGTCTGTTG-30
(reverse); BAFF—50-TTGAGTCTGGTGACTTTGTTTCG-30 (forward) and
50-GCAAGTTGGAGTTCATCTCCTT-30 (reverse); CCR7—50-TGAGGT-
CACGGACGATTACAT-30 (forward) and 50-GTAGGCCCACGAAACAAAT-
GAT-30 (reverse); CCL19—50-CTGCTGGTTCTCTGGACTTCC-30 (forward)
and 50-AGGGATGGGTTTCTGGGTCA-30 (reverse); and CCL21—50-
GTTGCCTCAAGTACAGCCAAA-30 (forward) and 50-ACAGGATAGCTGG-
GATGG-30 (reverse).
Statistical analysis
Data analysis was performed using IBM-SPSS version 13.0 (IBM,
Armonk, NY). Inter-observer agreement with respect to the assess-
ment of inﬂammation before the consensus meeting of the 2 observ-
ers was expressed as weighted Cohen's κ. Mann–Whitney U test or
Kruskal–Wallis test with Dunn's test for multiple comparison was
employed to compare cytokine expression among different groups.
Fisher exact test was employed to compare frequencies between pSS
and controls or among pSS patient subgroups. Binary logistic
regression was used to identify possible association between clinical
and serological features and the presence of GC. The signiﬁcance level
was 2 sided and set at p o 0.05.Results
Demographic and clinical characteristics of pSS patients
Table 1 summarizes clinical, serological, and histological fea-
tures of pSS patients. All data were recorded at the time of
diagnosis. Our cohort included 98 females and 6 males with a
mean age, at diagnosis, of 52 7 12 years. Of 104 patients, 92 (88%)
complained ocular symptoms while 89 (86%) experienced oral
symptoms. In 22 (21%) patients, salivary gland swelling was
reported, and in 73 (70%) patients, extraglandular involvement
occurred. Over 50% of patients displayed anti-Ro/SSA antibodies
and, of these, 25% displayed both anti-Ro/SSA and anti-La/SSB
antibodies.
Histological analysis of MSG biopsies
As far as the histological patterns are concerned, Table 2
summarizes the scoring systems employed in the study.
Table 1
Clinical, laboratory, and histological characteristics of patients with primary Sjog̈ren's syndrome
pSS total (n ¼ 104) GCþ (n ¼ 58) GC (n ¼ 46) p Value
Mean age at diagnosis (years) 52 49 55 0.02
Proportion of female patients (%) 98 (94) 56 (96) 42 (91) ns
Ocular symptoms (%) 92 (88) 52 (90) 40 (87) ns
Oral symptoms (%) 89 (86) 49 (84) 40 (87) ns
Salivary gland swelling (%) 22 (21) 19 (33) 3 (6) 0.001
Extraglandular manifestations (%) 73 (70) 41 (71) 32 (70) ns
Lymphadenopathy involvement (%) 27 (26) 18 (31) 9 (20) ns
Articular involvement (%) 47 (45) 28 (48) 19 (41) ns
Cutaneous involvement (%) 12 (11) 7 (12) 5 (11) ns
Pulmonary involvement (%) 12 (11) 6 (10) 6 (13) ns
Renal involvement (%) 4 (4) 2 (3) 2 (4) ns
Muscular involvement (%) 2 (2) 1 (2) 1 (2) ns
Peripheral nervous system involvement (%) 10 (10) 5 (9) 5 (11) ns
Central nervous system involvement (%) 5 (5) 1 (2) 4 (9) ns
Gastrointestinal involvement (%) 14 (13) 10 (17) 4 (9) ns
Raynaud's phenomenon (%) 34 (33) 18 (31) 16 (35) ns
Leukopenia (%) 29 (28) 17 (29) 12 (26) ns
Hypergammaglobulinemia (%) 34 (33) 28 (48) 6 (13) 0.0001
Hypocomplementemia (%) 12 (11) 8 (14) 4 (9) ns
Lymphoma (%) 2 (2) 2 (3) 0 (0) ns
Antinuclear antibody (ANA) (%) 80 (77) 51 (88) 29 (63) 0.004
Anti-Ro (SSA) antibody (%) 58 (56) 49 (84) 9 (20) o0.0001
Anti-La (SSB) antibody (%) 28 (27) 26 (45) 2 (4) o0.0001
Anti-Ro (SSA) and anti-La (SSB) antibody (%) 26 (25) 25 (43) 1 (2) o0.0001
Rheumatoid factor (%) 33 (32) 23 (40) 10 (22) 0.05
Mean focus score 2 2 1 o0.0001
FLS (%) 104 (100) 58 (100) 46 (100) ns
Chisholm and Mason grade 3 (%) 42 (40) 10 (17) 32 (70) o0.0001
Chisholm and Mason grade 4 (%) 62 (60) 48 (83) 14 (30) o0.0001
Tarpley score 1 (%) 50 (48) 14 (24) 36 (78) o0.0001
Tarpley score 2 (%) 12 (11) 6 (10) 6 (13) ns
Tarpley score 3 (%) 21 (20) 18 (31) 3 (6) 0.003
Tarpley score 4 (%) 21 (20) 20 (34) 1 (2) o0.0001
Severity of inﬂammatory inﬁltrate 5 (%) 104 (100) 58 (100) 46 (100) ns
p Value for the differences between patients with (GCþ) and without (GC) germinal centers in minor salivary gland biopsies. Frequencies compared with Fisher exact test
and continuous variables with Mann–Whitney U test. ns, not signiﬁcant; FLS, focal lymphocytic sialadenitis.
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and the histological diagnosis of pSS was high (Cohen's κ ¼ 0.87).
Disagreements were easily resolved by consensus between observ-
ers. A total of 42 (40%) patients displayed 1 focus in 4 mm2 of
salivary tissue and a Chisholm and Mason grade 3. Conversely, in
62 (60%) patients, the number of foci in 4 mm2 was 41, corre-
sponding to a Chisholm and Mason grade 4. According to the
different extent of glandular architecture derangement, 50 (48%)
patients displayed a Tarpley score 1, 12 (11%) patients a Tarpley
score 2, 21 (20%) patients a Tarpley score 3, and 21 (20%) patients a
Tarpley score 4. Of 104 patients, 58 (56%) displayed GC-like
structures at the time of diagnosis. MSGs of GCþ patients showed
a glandular inﬁltrate with B/T compartmentalization and positivityTable 2
Histological patterns and scoring systems in MSG biopsy
Histological
pattern
Chisholm and Mason
grading system
Tarpley
score
Severity of
inﬂammatory inﬁltrate
Normal 0 1
NSCS 1 0 2
3
SCS 2 4
FLS 3 1 5
24
3
4
NSCS, non-speciﬁc chronic sialadenitis; SCS, sclerosing chronic sialadenitis; FLS,
focal lymphocytic sialadenitis; MSG, minor salivary gland. For detailed information
concerning each scoring system, please refer to the article and corresponding
references.for fDCs, while in the majority of GC patients, the B/T compart-
mentalization was absent. Figure 1 displays representative MSGs
of a patient with (A–C) and a patient without (D–F) GC-like
structures.
GCþ /GC patient analysis
When pSS patients were divided according to the presence or
absence of GC-like structures in MSGs (Table 1), we observed that
GCþ patients received a diagnosis of pSS at a younger age (49 7
12 vs 55 7 12 years, p ¼ 0.02) and experienced more frequently
salivary gland swelling compared to those without GC (33% vs 6%,
p ¼ 0.001). Furthermore, GCþ patients displayed more frequently
hypergammaglobulinemia, anti-Ro/SSA antibodies, anti-La/SSB
antibodies, the combination of anti-Ro/SSA and anti-La/SSB anti-
bodies (all p o 0.0001), antinuclear antibodies (ANA), and
rheumatoid factor (RF) positivity (p ¼ 0.004 and 0.05, respec-
tively). To note, GCþ subgroup showed a higher prevalence of
Tarpley score 3 or 4 (p ¼ 0.003 and o0.0001, respectively) as well
as a higher prevalence of Chisholm and Mason grade 4 (p o
0.0001).
Therefore, we subsequently performed binary logistic regres-
sion in order to quantify the strength of the association between
GCs and other histological, clinical, and serological variables. As
shown in Table 3, patients displaying either anti-Ro/SSA or the
association of anti-Ro/SSA and anti-La/SSB antibodies had higher
odds ratios (ORs) of having a GC-like structure (13.5 and 98,
respectively; both p o 0.0001). An association with GCs was also
observed concerning hypergammaglobulinemia (OR ¼ 6.3), sali-
vary gland swelling (OR ¼ 7.2) (both p o 0.01), and Tarpley score
Fig. 1. Histological evaluation of pSS MSGs in a representative patient with (A–C) or without (D–F) GC-like structures. (A and D) Hematoxylin and eosin staining at
4 magniﬁcation. (B and E) The double staining with anti-CD3 (red) and anti-CD20 (green) at 20 magniﬁcation in the square area highlighted in (A) and (D), respectively.
(C and F) The staining with anti-CD21 at 20 magniﬁcation in the square area highlighted in (B) and (E), respectively. Nuclear counterstaining was performed with DAPI
(B, C, E, and F). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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patients, a signiﬁcant association with extraglandular involvement
was also highlighted (OR ¼ 4.5, p ¼ 0.005). When all these
variables were analyzed by multivariate analysis, we observed that
only the extraglandular involvement was independently associ-
ated to GC presence (OR ¼ 5.3, p o 0.004), thereby conﬁrming the
increased risk to develop a more severe disease in GCþ patients.
Molecular analysis of MSG biopsies
Subsequently, we moved to assess cytokines and chemokines
known to be involved, not only in the induction and development
of glandular damage in pSS, but also in ectopic lymphoneogenesis
and GC formation. As displayed in Supplementary Table S1, the 50
pSS patients whose MSGs were available for molecular analysis
resembled clinical, serological, and histological features of the
global study cohort.
A total of 30 subjects with sicca symptoms and either normal
MSG or NSCS were used as controls. As depicted in Figure 2A, pSSTable 3
Univariate and multivariate logistic regression analysis of factors associated with the pr
Variable Univariate
OR 95% CI
Anti-Ro/SSA antibodya 13 4.4–41
Anti-Ro/SSA and anti-La/SSB antibodya 98 11.7–829
Hypergammaglobulinemia 6.3 2.3–17
Salivary gland swelling 7.2 1.9–26
Tarpley score 4 2.4–7
Focus score 4 2.1–8
Extraglandular involvement 4.5 1.6–12.6
OR, odds ratio; CI, conﬁdence interval.
a Compared to pSS patients with negative anti-Ro/SSA and anti-La/SSB antibodies.patients displayed higher levels of all tested cytokines compared to
normal MSGs (all p o 0.0001). A similar behavior was observed
when pSS patients where compared to subjects with NSCS (all p o
0.0001). No difference was observed between normal MSGs and
NSCS MSGs for any of the evaluated cytokines.
According to the severity of inﬂammatory inﬁltrate, we strati-
ﬁed subjects with normal MSGs (severity grade 1) and NSCS
(severity grade from 2 to 4) in order to identify any differences
concerning the assessed molecules between these 2 subsets.
Figure 2B displays that NSCS cytokine proﬁle does not differ from
that of normal MSGs except for CXCL13 which appears higher in
subjects with a severity grade of 4 with respect to normal MSGs
(p o 0.0001). In addition, CXCL13 was more expressed in subjects
with severity grade 4 compared to those with severity grades
2 and 3 (both p o 0.05). pSS patients (severity grade 5) displayed
higher levels of all tested cytokines when compared to normal
MSGs (all p o 0.0001). Moreover, pSS patients displayed higher
levels of all the tested cytokines, when compared to patients with
severity of inﬂammatory inﬁltrate grades 2, 3, and 4 (all p o 0.05).esence of germinal centers
Multivariate
p Value OR 95% CI p Value
o0.0001 0.7 0.4–2.2 0.4
o0.0001 0.6 0.3–1.3 0.2
0.0003 0.6 0.2–2.3 0.5
0.003 2.5 0.5–11.6 0.3
o0.0001 0.9 0.5–1.9 0.9
o0.0001 0.8 0.4–1.5 0.5
0.005 5.3 1.7–16.7 0.004
Fig. 2. Cytokine expression according to the histological pattern (A) and the severity of inﬂammatory inﬁltrate (B). Bars indicate mean 7 standard error of the mean (SEM).
(A) #p o 0.0001 FLS vs normal; *p o 0.0001 FLS vs NSCS. (B) #p o 0.0001 grade 5 vs grade 1; *p o 0.05 grade 5 vs grade 2; p o 0.05 grade 5 vs grade 3; Δp o 0.05 grade
5 vs grade 4; §p o 0.0001 grade 4 vs grade 1; 1p o 0.05 grade 4 vs grade 2; ^p o 0.05 grade 4 vs grade 3. Data analysis was performed with Kruskall–Wallis test and Dunn's
test for multiple comparison. FLS, focal lymphocytic sialadenitis; NSCS, non-speciﬁc chronic sialadenitis.
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Mason grade 3 (1 focus/4 mm2) or 4 (41 focus/4 mm2) may
reﬂect any differences in the cytokine pattern of pSS patients,
compared to grade 0 (normal MSG) or 1 and 2 (NSCS) (Fig. 3A). We
observed that pSS patients with Chisholm and Mason grade
4 displayed higher levels of all the assessed cytokines when
compared to subjects with Chisholm and Mason grade 0 (all
p o 0.0001). Furthermore, pSS patients with a Chisholm and
Mason grade 4 displayed higher levels of all cytokines whencompared to both Chisholm and Mason grades 1 and 2 (all p o
0.05). CXCR4, CXCR5, and CCR7 were the only cytokines found to
be higher in pSS patients with Chisholm and Mason grade
4 compared to pSS patients with Chisholm and Mason grade 3
(all p o 0.05).
Then we divided pSS patients according to Tarpley score and
observed that patients with Tarpley score Z1 displayed higher
levels of all the assessed cytokines when compared to subjects
with Tarpley score 0. Moreover, pSS patients with massive
Fig. 3. Cytokine expression according to the Chisholm and Mason grading system (A) and the Tarpley score (B). Bars indicate mean 7 standard error of the mean (SEM).
(A) #p o 0.0001 grade 4 vs grade 0; *p o 0.05 grade 4 vs grade 1; §p o 0.05 grade 4 vs grade 2; 1p o 0.05 grade 3 vs grade 0; Δp o 0.05 grade 3 vs grade 1; p o 0.05 grade
3 vs grade 2. (B) #p o 0.0001 grade 4 vs grade 0; 1p o 0.05 grade 4 vs grade 1; *p o 0.0001 grade 3 vs grade 0; ^p o 0.05 grade 3 vs grade 1; §p o 0.0001 grade 2 vs grade 0;
p o 0.05 grade 2 vs grade 1; Δp o 0.05 grade 1 vs grade 0. Data analysis was performed with Kruskall–Wallis test and Dunn's test for multiple comparison.
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higher levels of all the tested cytokines, when compared to those
with minimum glandular damage (Tarpley score 1). Of interest,
pSS patients with Tarpley score 2 displayed higher levels of all the
cytokines (all p o 0.05) compared to Tarpley score 1 and those
with Tarpley score 3 displayed higher levels of all cytokines
compared to Tarpley score 1 (all p o 0.05) (Fig. 3B). No differenceswere observed between patients with Tarpley scores 2, 3,
and 4.
Finally, we analyzed the cytokine pattern of pSS patients
according to the presence or absence of GCs and observed that
all cytokines were more expressed in samples displaying GC-like
structures compared to those without GCs (all p o 0.001;
Fig. 4).
Fig. 4. Cytokine expression according to the presence or absence of germinal center (GC)-like structures. Bars indicate mean 7 SEM. #p o 0.0001 GCþ vs normal; *p o 0.01
GCþ vs GC; 1p o 0.05 GC vs normal. Data analysis was performed with Kruskall–Wallis test and Dunn's test for multiple comparison.
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Glandular inﬂammatory inﬁltrate and ectopic lymphoneogen-
esis, occurring in MSGs of patients with pSS, represent a powerful
tool to shed some light on pSS pathogenesis. Furthermore, the
identiﬁcation of a relationship between histological features and
clinical picture may help to predict both disease evolution and
prognosis. In the present study, we assessed several speciﬁc
histological, molecular, clinical, and serological features in a large
cohort of pSS patients and subsequently, by multivariate analysis,
we compared these pSS features in order to identify biomarkers
potentially helpful in a clinical setting.
To date, MSG biopsy represents the “gold standard” for pSS
diagnosis. Although it is an invasive intervention, it is an easy
procedure and complications are rarely reported. Besides pSS, MSG
biopsy has been employed for the diagnosis of other systemic
disorders, such as amyloidosis, sarcoidosis, IgG4-related disease,
and neonatal hemochromatosis [55]. The presence of FLS with a
focus score Z1 in glandular tissue is a major criterion that allows
pSS diagnosis. Indeed, MSG biopsy has proven to have a high
speciﬁcity and positive predictive value, with a sensitivity ranging
from 63.5% to 93.7% [13]. These peculiar features make MSG biopsy
particularly helpful to evaluate patients with non-speciﬁc clinical
manifestations, extraglandular involvement, very early disease,
and/or autoantibodies negativity.
Several histological scores have been reported in literature to
describe the glandular involvement during pSS. However, although
the presence of foci is a hallmark of the disease, different patterns
based on the quantiﬁcation of inﬂammatory inﬁltrate may be
observed. Moreover, the amount of the inﬂammatory inﬁltrate
appeared to correlate with several demographic, clinical, and
serological features [56].
The Chisholm and Mason grading system considers MSGs with
normal architecture (grade 0), slight and moderate inﬁltrate
(grades 1 and 2, respectively), presence of 1 focus (grade 3), and
more than 1 focus in 4 mm2 [6]. The Tarpley score highlights only
the absence (score 0) or the presence (scores 1–4) of foci in 4 mm2
of glandular tissue, with the higher scores identifying glands with
many foci and consequent progressive derangement of glandulartissue [7]. Finally, in order to assess and quantify the presence of
inﬂammatory cells, some authors proposed an inﬂammatory
severity score including (i) normal MSGs (score 1), (ii) MSGs
with different amounts of inﬂammatory cells (scores 2–4), and
(iii) the presence of 1 or more foci in 4 mm2 (score 5) [8–10].
The main limitations of these classical score systems is to be
conﬁned to the diagnostic setting, and H&E staining allows
only to quantify the inﬂammatory inﬁltrate and foci number,
without giving information concerning qualitative features of the
inﬁltrate. Therefore, we speculated that a molecular approach on
one hand and different histological techniques such as immuno-
ﬂuorescence and immunochemistry on the other may provide the
clinicians with a wide range of additional information for each pSS
patient.
To reach this goal, we performed these 2 approaches, at the
same time, and attempted to ﬁnd a rationale for their employment
in clinical practice. Previous studies were aimed to identify the
prevalence of GCs in pSS patients, reporting percentages ranging
from 18% to 59% [23]. However, the prevalence of GCþ patients in
our cohort was 56%, of the total number of patients reported, and
it was higher than those reported in available literature. Such
discrepancy may be due to the different histological approach of
our study, which was based not only on H&E staining, but
evaluating the B-/T-cells compartmentalization, together with
the possible presence of CD21þ cells, in the inﬂammatory inﬁl-
trate, by immunoﬂuorescence. From a clinical point of view, our
data show that ectopic GC formation in exocrine glands is
associated with a more severe disease, and GCþ patients are
diagnosed with pSS at a younger age. Indeed, GCþ patients
experienced more frequently extraglandular manifestations, sali-
vary gland swelling, hypergammaglobulinemia, and autoantibody
production, when compared to GC patients. Therefore, it is
conceivable that these patients, with a more severe disease, refer
to the rheumatologists earlier than patients with mild clinical
manifestations, who do not display GC. To note, the evidence that
extraglandular involvement was independently associated to GC
presence, at multivariate analysis, is in line with previous reports
and appears to conﬁrm the link between ectopic lymphoneo-
genesis and a more severe clinical picture.
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ated with a more severe glandular involvement as suggested by
both higher focus score and higher histopathological scores.
Taking into account the pivotal role of GCs in driving B- and T-
cell activation, it has been suggested that their presence in the pSS
glandular inﬁltrates may affect the clinical picture and the pro-
gression of the disease in several ways [57]: (i) the higher degree
of lymphocytic organization may lead to a more pronounced
disruption of glandular architecture and secretory function impair-
ment [31,58]; (ii) GC formation may increase lymphocyte activa-
tion and function, autoantibody production [57], and immune
complex formation, leading to extraglandular manifestations
[57–59]; and (iii) the development of B-cell NHL seems to rely
on antigen-driven stimulation [60].
Ectopic lymphoid tissue represents a common ﬁnding in
several autoimmune diseases, such as RA and pSS, where syno-
vium, exocrine glands, and other tissues are chronically inﬂamed.
The formation of GC-like structures is the result of a multi-step
dynamic process involving immune cells, epithelial cells, high
endothelial venules, chemokines, cytokines, growth factors, and
related receptors. In particular, evidence from animal models and
pSS patients showed that the formation and maintenance of
tertiary lymphoid tissues is critically dependent on the ectopic
expression of Ltα and Ltβ, CXCL13, CXCL12, CCL19, and CCL21, as
well as their interactionwith speciﬁc receptors, CXCR5, CXCR4, and
CCR7, respectively [17,42]. In addition, BAFF is involved in B-cell
survival and humoral immune responses, playing a critical role in
B-cell homeostasis [36].
Therefore, in patients developing GC-like inﬁltrates, a different
genetic, serological, and glandular cytokine proﬁle is detectable
compared to those without GC structures or healthy controls [24–27].
In our study, a subgroup of 50 patients with clinical, serological,
and histopathological features overlapping that of the global study
cohort, were evaluated to quantify the expression of chemokines,
cytokines, and related receptors, involved in glandular inﬂamma-
tory process and lymphoneogenesis at mRNA level. Our results
mirror what is already observed in the aforementioned studies,
since we observed higher levels of Ltα, Ltβ, BAFF, CXCR4, CXCL12,
CXCR5, CXCL13, CCR7, CCL19, and CCL21 in FLS MSGs when
compared to normal MSGs or NSCS patterns. However, we show,
for the ﬁrst time, a global overview concerning many of the key
cytokines involved in pSS pathogenesis, pointing out their recip-
rocal correlation and the association with MSG involvement.
On this basis, the presence of FLS, and consequently the ectopic
lymphoid tissue, seems to be strictly related to, and dependent on,
the expression of inﬂammatory cytokines such as Ltα and Ltβ; the
activation CXCL12/CXCR4, CXCL13/CXCR5, and CCR7/CCL19–CCL21
pathways; and the evidence of higher amounts of BAFF.
To note, a similar behavior was observed when patients were
stratiﬁed according to other histological score systems such as the
severity of inﬂammatory inﬁltrate, the Chisholm and Mason
grading system, and the Tarpley score. In particular, we showed
that the worse was the inﬂammatory inﬁltrate, the higher were
the value of histological score and the levels of molecular expres-
sion. These ﬁndings point out that the increasing severity of the
histological pattern and the organization of the inﬂammatory
inﬁltrate parallel the increasing amounts of the assessed cytokine
proﬁle. Noteworthy, when we stratiﬁed patients according to the
presence or absence of GC, we observed that GCþ patients
displayed higher levels of Ltα, Ltβ, BAFF, CXCR4, CXCL12, CXCR5,
CXCL13, CCR7, CCL19, and CCL21 when compared to GC patients.
These data conﬁrm the role of these cytokines in the formation of
ectopic GC-like structures, B-/T-cell compartmentalization, and
fDCs recruitment.
Furthermore, patients who developed GC-like inﬁltrates dis-
played not only a different clinical and serological proﬁle, but alsoa different histological and glandular cytokine proﬁle, when
compared to those without GC structures or healthy controls.
These ﬁndings deserve some consideration from a therapeutic
point of view. We recently correlated the clinical response to the
immune-histological and molecular patterns in a large cohort of
pSS patients treated with a chimeric humanized monoclonal anti-
CD20 antibody (rituximab; RTX) [61]. We showed that this therapy
is able to interfere with the formation of tertiary lymphoid tissue,
not only depleting B-cells, but also tuning the delicate equilibrium
between cells, molecules, and receptors, partially affecting the pro-
B-cell inﬂammatory milieu that is typical of the inﬂamed glands. In
particular, MSGs of pSS patients treated with RTX showed the
higher rate of GC disappearance, and this datum was correlated
with a decrease of the expression at mRNA level of CXCR4 and
CXCR5 in the samples from the affected glands, which mirrored
the lack of CXCR4þ and CXCR5þ cells in the inﬁltrates. Further-
more, an increased level of CXCL12 and CXCL13, without any effect
concerning the BAFF expression, was also reported.Conclusion
Our study provides evidence that different histopathological
features and scoring reﬂect different degrees of inﬂammation and
cytokine expression on one hand, and different clinical patterns,
including autoantibodies production and extraglandular involve-
ment, on the other. In order to improve in clinical practice the
classical histopathological report, it may be helpful to include
more detailed information concerning the focus score, such as
B-/T-cell compartmentalization and GC presence, to support clini-
cians in planning their diagnostic and therapeutic approach.
Furthermore, we conﬁrmed that BAFF, LTα and LTβ, CXCR4/CXCL12,
CXCR5/CXCL13, and CCR7/CCL19–CCL21 axis play a pivotal role in
chronic activation of the immune system, leading to GC formation
and probably are involved in disease progression and development
of severe complications.Acknowledgments
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